e-Therapeutics PLC ETX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 9.18
- Day Range
- GBX 8.54–9.67
- 52-Week Range
- GBX 8.00–24.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 5.61 Bil
- Volume/Avg
- 2.2 Mil / 731,898
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 153.43
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 37
- Website
- https://www.etherapeutics.co.uk
Comparables
Valuation
|
Metric
|
ETX
|
ZURA
|
BVXP
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 28.17 |
Price/Book Value | 1.94 | 2.66 | 20.20 |
Price/Sales | 153.43 | — | 17.27 |
Price/Cash Flow | — | — | 25.71 |
Price/Earnings
ETX
ZURA
BVXP
Financial Strength
|
Metric
|
ETX
|
ZURA
|
BVXP
|
|---|---|---|---|
Quick Ratio | 21.70 | 4.92 | 6.69 |
Current Ratio | 22.20 | 4.97 | 7.04 |
Interest Coverage | −827.07 | — | — |
Quick Ratio
ETX
ZURA
BVXP
Profitability
|
Metric
|
ETX
|
ZURA
|
BVXP
|
|---|---|---|---|
Return on Assets (Normalized) | −33.43% | −71.08% | 68.76% |
Return on Equity (Normalized) | −35.02% | −139.85% | 77.21% |
Return on Invested Capital (Normalized) | −36.22% | −99.89% | 76.10% |
Return on Assets
ETX
ZURA
BVXP
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mmpppdfzjd | Bxf | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pfcntdmm | Wdlfzn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vwjyfybht | Yygmbds | $97.8 Bil | |
MRNA
| Moderna Inc | Yrbjglczp | Xrpc | $38.8 Bil | |
ARGX
| argenx SE ADR | Xphqxpqst | Tdmr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qrvvyyry | Mbxwj | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dlwydynb | Fgjns | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nxpbnjmb | Ymxxtx | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Tcdfprrldl | Rhrfqdv | $12.5 Bil | |
INCY
| Incyte Corp | Vvbjyxp | Cssgsm | $11.5 Bil |